Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Merck Sharpe and Dohme reports satisfaction with 2010 performance

Merck Sharpe and Dohme reports satisfaction with 2010 performance

7th February 2011

Merck Sharpe and Dohme has published financial data for 2010, its first full year of operation since its merger with Schering-Plough in 2009.

The pharmaceutical giant generated $45.99 billion (28.52 billion pounds) during the 12 months, with data specific to the fourth quarter showing double-digit percentage earnings growth.

During the year, the firm made significant progress towards its cost reduction initiatives, with more than $2 billion in net synergy savings having been achieved.

Strong sales growth was seen for products such as Janumet, Singulair, Remicade and Isentress, while more than ten treatments are currently being launched in key global markets.

In 2011, Merck Sharpe and Dohme now expects revenue growth in the low to mid-single digit range.

Kenneth Frazier, the organisation's president and chief executive officer, said: "These results clearly demonstrate the benefits of the post-merger Merck with our broader product portfolio, robust late-stage pipeline and expanded global footprint."

Earlier this month, the company published new clinical trial data for its human papillomavirus drug Gardasil, demonstrating its potential benefits among male patients.ADNFCR-8000103-ID-800388395-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.